Näytetään tulokset 1 - 10 / 21
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia

Vertaisarvioitu
DOI
10.1097/MPH.0000000000000642
Levinsen, Mette; Harila-Saari, Arja; Grell, Kathrine; Jonsson, Olafur Gisli; Taskinen, Mervi; Abraha...
Journal of pediatric hematology oncology2016 Julkaisujen tiedon ikoni

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/leu.2016.314
Malani, D.; Murumagi, A.; Yadav, B.; Kontro, M.; Eldfors, S.; Kumar, A.; Karjalainen, R.; Majumder, ...
Leukemia2017 Julkaisujen tiedon ikoni

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia:

Vertaisarvioitu
Avoin saatavuus
Kolonen A; Sinisalo M; Huhtala H; Rimpiläinen J; Rintala H; Sankelo M; Koivunen E; Silvennoinen R; R...
European Journal of Haematology2022 Julkaisujen tiedon ikoni

Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.biopha.2023.115352
Rodríguez-Vázquez, Gabriel O.; Diaz-Quiñones, Adriana O.; Chorna, Nataliya; Salgado-Villanueva, Iris...
Biomedicine & Pharmacotherapy2023 Julkaisujen tiedon ikoni

Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy

Vertaisarvioitu
DOI
10.1097/CAD.0b013e32834ee315
Nygaard, Randi; Kivivuori, Sanna-Maria
Anti-cancer drugs2012 Julkaisujen tiedon ikoni

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the

Vertaisarvioitu
Kolonen A; Sinisalo M; Huhtala H; Rimpiläinen J; Rintala H; Sankelo M; Koivunen E; Silvennoinen R; R...
European Journal of Haematology2022 Julkaisujen tiedon ikoni

Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia : Long‐term results of the prospective randomized nationwide AML ‐2003 study by the Finnish Leukemia Group

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/ejh.13805
Kolonen, Aarne; Sinisalo, Marjatta; Huhtala, Heini; Rimpiläinen, Johanna; Rintala, Hannele; Sankelo,...
European journal of haematology2022 Julkaisujen tiedon ikoni

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

Vertaisarvioitu
DOI
10.3109/10428194.2012.672736
Räty, Riikka; Honkanen, Tuomo; Jantunen, Esa; Jyrkkio, Sirkku; Karjalainen-Lindsberg, Marja-Liisa; K...
Leukemia & lymphoma2012 Julkaisujen tiedon ikoni

Total body irradiation after high-dose cytarabine in mantle cell lymphoma:a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

DOI
10.1038/leu.2015.322
Hoster, E.; Geisler, C. H.; Doorduijn, J.; van der Holt, B.; Walewski, J.; Bloehdorn, J.; Ribrag, V....
Leukemia2016 Julkaisujen tiedon ikoni

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation:early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

DOI
10.3109/10428194.2013.825906
Laurell, Anna; Kolstad, Arne; Jerkeman, Mats; Räty, Riikka; Geisler, Christian H.
Leukemia & lymphoma2014

Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia

Vertaisarvioitu
DOI
10.1097/MPH.0000000000000642
2016

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/leu.2016.314
2017

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia:

Vertaisarvioitu
Avoin saatavuus
2022

Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.biopha.2023.115352
2023

Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy

Vertaisarvioitu
DOI
10.1097/CAD.0b013e32834ee315
2012

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the

Vertaisarvioitu
2022

Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia : Long‐term results of the prospective randomized nationwide AML ‐2003 study by the Finnish Leukemia Group

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/ejh.13805
2022

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

Vertaisarvioitu
DOI
10.3109/10428194.2012.672736
2012

Total body irradiation after high-dose cytarabine in mantle cell lymphoma:a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

DOI
10.1038/leu.2015.322
2016

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation:early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

DOI
10.3109/10428194.2013.825906
2014